Three-year follow-up of the MULTIcentre evaluation of Single high-dose Bolus TiRofiban versus Abciximab with Sirolimus-eluting STEnt or Bare-Metal Stent in Acute Myocardial Infarction StudY (MULTISTRATEGY)

International Journal of Cardiology

Volumn 165, Issue 1, 2013, Pages 134-141

  Valgimigli, Marco ^a,b   Campo, Gianluca ^a   Gambetti, Stefania ^a   Bolognese, Leonardo ^c   Ribichini, Flavio ^d   Colangelo, Salvatore ^e   De Cesare, Nicoletta ^f   Rodriguez, Alfredo E ^g   Russo, Filippo ^h   Moreno, Raul ⁱ   Piva, Tommaso ^j   Sheiban, Imad ^k   Penzo, Carlo ^l   Prati, Francesco ^m   Nazzaro, Marco S ⁿ   Díaz Fernández, José F ^o   Vassanelli, Corrado ^d   Parrinello, Giovanni ^p   Ferrari, Roberto ^a,b  

^a UNIVERSITY OF FERRARA   (Italy)

^b IRCCS   (Italy)

^c IRCCS POLICLINICO SAN DONATO   (Italy)

^d UNIVERSITY OF VERONA   (Italy)

^e MOLINETTE HOSPITAL   (Italy)

^f Policlinico S Marco   (Italy)

^g Sanatorio Otamendi y Miroli   (Argentina)

^h FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

ⁱ HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^j Azienda Ospedaliero Universitaria   (Italy)

^k UNIVERSITY OF TURIN   (Italy)

^l Civic Hospital   (Italy)

^m CATHOLIC UNIVERSITY   (Italy)

ⁿ SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^o HOSPITAL JUAN RAMÓN JIMÉNEZ   (Spain)

^p UNIVERSITY OF BRESCIA   (Italy)

more..

Author keywords

Abciximab; High dose Bolus Tirofiban; Primary percutaneous coronary intervention; Sirolimus stent

Indexed keywords

ABCIXIMAB; RAPAMYCIN; TIROFIBAN;

ADULT; AGED; ARTICLE; BARE METAL STENT; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG ELUTING STENT; DRUG MEGADOSE; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REOPERATION; RISK FACTOR; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; CLINICAL EFFECTIVENESS; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDY; SAFETY; SINGLE DRUG DOSE; SIROLIMUS ELUTING STENT;

AGED; ANTIBODIES, MONOCLONAL; DRUG THERAPY, COMBINATION; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; METALS; MIDDLE AGED; MYOCARDIAL INFARCTION; PROSPECTIVE STUDIES; SIROLIMUS; STENTS; TREATMENT OUTCOME; TYROSINE;

EID: 84876141722     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2011.07.106     Document Type: Article

References (30)

1. J. Mehilli, A. Kastrati, and S. Schulz Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial Circulation 119 2009 1933 1940
2. R. Mehran, A.J. Lansky, and B. Witzenbichler Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial Lancet 374 2009 1149 1159
3. S.G. Goodman, W. Huang, and A.T. Yan The expanded global registry of acute coronary events: baseline characteristics, management practices, and hospital outcomes of patients with acute coronary syndromes Am Heart J 158 2009 193 201 [e1-5]
4. K. Huber, D.R. Holmes Jr., and A.W. van 't Hof Use of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention: insights from the APEX-AMI trial Eur Heart J 31 2010 1708 1716
5. J.M. ten Berg, A.W. van 't Hof, and T. Dill Effect of early, pre-hospital initiation of high bolus dose tirofiban in patients with ST-segment elevation myocardial infarction on short- and long-term clinical outcome J Am Coll Cardiol 55 2010 2446 2455
6. A.W. Van't Hof, J. Ten Berg, and T. Heestermans Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial Lancet 372 2008 537 546
7. E.M. Antman, M. Hand, and P.W. Armstrong 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines: developed in collaboration with the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction, writing on behalf of the 2004 writing committee Circulation 117 2008 296 329
8. G. Montalescot, D. Antoniucci, and A. Kastrati Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up Eur Heart J 28 2007 443 449
9. A.J. Reininger, J. Agneskirchner, and P.A. Bode c7E3 Fab inhibits low shear flow modulated platelet adhesion to endothelium and surface-absorbed fibrinogen by blocking platelet GP IIb/IIIa as well as endothelial vitronectin receptor-results from patients with acute myocardial infarction and healthy controls Thromb Haemost 83 2000 217 223
10. M. Valgimigli, G. Biondi-Zoccai, and M. Tebaldi Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials Eur Heart J 31 2010 35 49
11. M. Tebaldi, C. Arcozzi, and G. Campo The 5-year clinical outcomes after a randomized comparison of sirolimus-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction J Am Coll Cardiol 54 2009 1900 1901
12. C. Spaulding Four year follow-up of the trial to assess the use of the CYPHer stent in acute myocardial infarction treated with BallOON angioplasty (TYPHOON) Oral presentation at Euro-PCR 2009 2009
13. R. Violini, C. Musto, and F. De Felice Maintenance of long-term clinical benefit with sirolimus-eluting stents in patients with ST-segment elevation myocardial infarction 3-year results of the SESAMI (sirolimus-eluting stent versus bare-metal stent in acute myocardial infarction) trial J Am Coll Cardiol 55 2010 810 814
14. A. Kaltoft, H. Kelbaek, L. Thuesen, J.F. Lassen, P. Clemmensen, L. Kløvgaard, T. Engstrøm, H.E. Bøtker, K. Saunamäki, L.R. Krusell, E. Jørgensen, H.H. Tilsted, E.H. Christiansen, J. Ravkilde, L. Køber, K.F. Kofoed, C.J. Terkelsen, and S. Helqvist Long-term outcome after drug-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: 3-year follow-up of the randomized DEDICATION (Drug Elution and Distal Protection in Acute Myocardial Infarction) Trial J Am Coll Cardiol 56 8 2010 641 645
15. M. Valgimigli, L. Bolognese, and M. Anselmi Two-by-two factorial comparison of high-bolus-dose tirofiban followed by standard infusion versus abciximab and sirolimus-eluting versus bare-metal stent implantation in patients with acute myocardial infarction: design and rationale for the MULTI-STRATEGY trial Am Heart J 154 2007 39 45
16. M. Valgimigli, G. Campo, and G. Percoco Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial Jama 299 2008 1788 1799
17. D.E. Cutlip, S. Windecker, and R. Mehran Clinical end points in coronary stent trials: a case for standardized definitions Circulation 115 2007 2344 2351
18. J.R. Anderson, K.C. Cain, and R.D. Gelber Analysis of survival by tumor response J Clin Oncol 1 1983 710 719
19. T.M. Therneau Modeling survival data: extending the cox model 2000 Springer-Verlag New York, NY
20. G. Montalescot, P. Barragan, and O. Wittenberg Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction N Engl J Med 344 2001 1895 1903
21. A.M. Lincoff Potent complementary clinical benefit of abciximab and stenting during percutaneous coronary revascularization in patients with diabetes mellitus: results of the EPISTENT trial Am Heart J 139 2000 S46 S52
22. E.J. Topol, D.B. Mark, and A.M. Lincoff Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT investigators. Evaluation of platelet IIb/IIIa inhibitor for stenting Lancet 354 1999 2019 2024
23. A. Kastrati, J. Mehilli, and J. Dirschinger Myocardial salvage after coronary stenting plus abciximab versus fibrinolysis plus abciximab in patients with acute myocardial infarction: a randomised trial Lancet 359 2002 920 925
24. R.M. Scarborough, N.S. Kleiman, and D.R. Phillips Platelet glycoprotein IIb/IIIa antagonists. What are the relevant issues concerning their pharmacology and clinical use? Circulation 100 1999 437 444
25. M. Valgimigli, G. Percoco, and P. Malagutti Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial Jama 293 2005 2109 2117
26. N.M. Ernst, H. Suryapranata, and K. Miedema Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarction J Am Coll Cardiol 44 2004 1187 1193
27. G.B. Danzi, C. Capuano, and M. Sesana Variability in extent of platelet function inhibition after administration of optimal dose of glycoprotein IIb/IIIa receptor blockers in patients undergoing a high-risk percutaneous coronary intervention Am J Cardiol 97 2006 489 493
28. J. Mehilli, A. Kastrati, and H. Schuhlen Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel Circulation 110 2004 3627 3635
29. E.J. Topol, D.J. Moliterno, and H.C. Herrmann Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization N Engl J Med 344 2001 1888 1894
30. H. Roukoz, A.A. Bavry, and M.L. Sarkees Comprehensive meta-analysis on drug-eluting stents versus bare-metal stents during extended follow-up Am J Med 122 581 2009 e1 e10